Literature DB >> 18193160

Thrombospondin-1: a physiological regulator of nitric oxide signaling.

J S Isenberg1, W A Frazier, D D Roberts.   

Abstract

Thrombospondin-1 is a secreted protein that modulates vascular cell behavior via several cell surface receptors. In vitro, nanomolar concentrations of thrombospondin-1 are required to alter endothelial and vascular smooth muscle cell adhesion, proliferation, motility, and survival. Yet, much lower levels of thrombospondin-1 are clearly functional in vivo. This discrepancy was explained with the discovery that the potency of thrombospondin-1 increases more than 100-fold in the presence of physiological levels of nitric oxide (NO). Thrombospondin-1 binding to CD47 inhibits NO signaling by preventing cGMP synthesis and activation of its target cGMP-dependent protein kinase. This potent antagonism of NO signaling allows thrombospondin-1 to acutely constrict blood vessels, accelerate platelet aggregation, and if sustained, inhibit angiogenic responses. Acute antagonism of NO signaling by thrombospondin-1 is important for hemostasis but becomes detrimental for tissue survival of ischemic injuries. New therapeutic approaches targeting thrombospondin-1 or CD47 can improve recovery from ischemic injuries and overcome a deficit in NO-responsiveness in aging. (Part of a Multi-author Review).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193160      PMCID: PMC2562780          DOI: 10.1007/s00018-007-7488-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  139 in total

1.  Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells.

Authors:  N Guo; H C Krutzsch; J K Inman; D D Roberts
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.

Authors:  M Streit; P Velasco; L F Brown; M Skobe; L Richard; L Riccardi; J Lawler; M Detmar
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression.

Authors:  M R Rossiello; S Momi; R Caracchini; S Giannini; G Guglielmini; A Monopoli; E Ongini; N Semeraro; M Colucci; P Gresele
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

4.  Thrombospondin-1 differentially induces chemotaxis and DNA synthesis of human venous smooth muscle cells at the receptor-binding level.

Authors:  Joanne S Lymn; Mahendra K Patel; Gerard F Clunn; Sarafina J Rao; Karen L Gallagher; Alun D Hughes
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

5.  Blood pressure relationship to nitric oxide, lipid peroxidation, renal function, and renal blood flow in rats exposed to low lead levels.

Authors:  Nurcan Dursun; Canan Arifoglu; Cem Süer; Leyla Keskinol
Journal:  Biol Trace Elem Res       Date:  2005-05       Impact factor: 3.738

6.  Thrombospondin-1 is a major activator of TGF-beta1 in vivo.

Authors:  S E Crawford; V Stellmach; J E Murphy-Ullrich; S M Ribeiro; J Lawler; R O Hynes; G P Boivin; N Bouck
Journal:  Cell       Date:  1998-06-26       Impact factor: 41.582

Review 7.  Epidemiology of myocardial infarction.

Authors:  Véronique L Roger
Journal:  Med Clin North Am       Date:  2007-07       Impact factor: 5.456

Review 8.  Nitric oxide. A novel signal transduction mechanism for transcellular communication.

Authors:  L J Ignarro
Journal:  Hypertension       Date:  1990-11       Impact factor: 10.190

Review 9.  Impact of outcomes research on the management of vascular surgery patients.

Authors:  John E Rectenwald; Gilbert R Upchurch
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

10.  CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Authors:  D W Dawson; S F Pearce; R Zhong; R L Silverstein; W A Frazier; N P Bouck
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

View more
  60 in total

1.  Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

Authors:  Sukhbir Kaur; Gema Martin-Manso; Michael L Pendrak; Susan H Garfield; Jeff S Isenberg; David D Roberts
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase.

Authors:  Keiko Takahashi; Raymond L Mernaugh; David B Friedman; Rebecca Weller; Nobuo Tsuboi; Hironobu Yamashita; Vito Quaranta; Takamune Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

3.  Emerging functions of matricellular proteins.

Authors:  David D Roberts
Journal:  Cell Mol Life Sci       Date:  2011-08-11       Impact factor: 9.261

4.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

Review 5.  Matricryptic sites control tissue injury responses in the cardiovascular system: relationships to pattern recognition receptor regulated events.

Authors:  George E Davis
Journal:  J Mol Cell Cardiol       Date:  2009-09-12       Impact factor: 5.000

6.  CD47 gene knockout protects against transient focal cerebral ischemia in mice.

Authors:  Guang Jin; Kiyoshi Tsuji; Changhong Xing; Yong-Guang Yang; Xiaoying Wang; Eng H Lo
Journal:  Exp Neurol       Date:  2009-02-20       Impact factor: 5.330

Review 7.  The counteradhesive proteins, thrombospondin 1 and SPARC/osteonectin, open the tyrosine phosphorylation-responsive paracellular pathway in pulmonary vascular endothelia.

Authors:  Anguo Liu; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  Microvasc Res       Date:  2008-10-01       Impact factor: 3.514

8.  Myeloid-specific deletion of thrombospondin 1 protects against inflammation and insulin resistance in long-term diet-induced obese male mice.

Authors:  Hasiyet Memetimin; Dong Li; Kaiyuan Tan; Changcheng Zhou; Ying Liang; Yadi Wu; Shuxia Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-23       Impact factor: 4.310

Review 9.  Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation.

Authors:  Manuel U Ramirez; Elizabeth R Stirling; Nancy J Emenaker; David D Roberts; David R Soto-Pantoja
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

10.  Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis.

Authors:  Kaiyong Yang; Jose L Vega; Muhamed Hadzipasic; Jean Pierre Schatzmann Peron; Bing Zhu; Yijun Carrier; Sharmila Masli; Luiz Vicente Rizzo; Howard L Weiner
Journal:  J Autoimmun       Date:  2009-02-01       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.